Rodas Flores J, Hernandez-Cruz B, Sanchez-Margalet V, Fernandez-Reboul Fernandez A, Fernandez Panadero E, Moral Garcia G
J Clin Med. 2025; 13(24.
PMID: 39768600
PMC: 11678567.
DOI: 10.3390/jcm13247677.
Triboulet F, Juge P, Truchetet M, Pham T, Roux N, Flipo R
RMD Open. 2025; 11(1.
PMID: 39762124
PMC: 11749054.
DOI: 10.1136/rmdopen-2024-005062.
Kurushima S, Koga T, Umeda M, Iwamoto N, Miyashita R, Tokito T
Front Immunol. 2024; 15:1501146.
PMID: 39737175
PMC: 11683115.
DOI: 10.3389/fimmu.2024.1501146.
Ahmed S, Lauran M, Ugwoke A, Walton T, Holroyd C, Galloway J
Rheumatol Adv Pract. 2024; 8(4):rkae127.
PMID: 39469493
PMC: 11513334.
DOI: 10.1093/rap/rkae127.
Shoda T, Kotani T, Koyama M, Yoshikawa A, Wada Y, Makino H
J Clin Med. 2024; 13(19).
PMID: 39407931
PMC: 11477086.
DOI: 10.3390/jcm13195871.
A Meta-Analysis Examining the Effect of Perioperative Biologic Disease-Modifying Anti-Rheumatic Medications on Postoperative Wound Complications in Various Orthopedic Surgeries.
Imam M, Alshahrani S, Alotaibi R, Almurayeh K, Alshabab N, Almutairi N
J Clin Med. 2024; 13(18).
PMID: 39337018
PMC: 11432387.
DOI: 10.3390/jcm13185531.
Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy.
Sullivan D, Ascherman D
Curr Rheumatol Rep. 2024; 26(12):431-449.
PMID: 39320427
DOI: 10.1007/s11926-024-01155-8.
Secondary hypogammaglobulinemia: diagnosis and management of a pediatric condition of clinical importance.
DiGiacomo D, Barmettler S
Curr Opin Pediatr. 2024; 36(6):659-667.
PMID: 39254658
PMC: 11560679.
DOI: 10.1097/MOP.0000000000001396.
Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project.
Spini A, LAbbate L, Ingrasciotta Y, Pellegrini G, Carollo M, Ientile V
Clin Epidemiol. 2024; 16:395-407.
PMID: 38854895
PMC: 11162210.
DOI: 10.2147/CLEP.S445120.
Potential impact of European Medicines Agency measures to minimize risk of serious side effects on JAKi prescribing and utilization in the UK.
Tian Z, Kearsley-Fleet L, Galloway J, Watson K, Lunt M, Hyrich K
Rheumatology (Oxford). 2024; 64(3):1453-1458.
PMID: 38748995
PMC: 11879295.
DOI: 10.1093/rheumatology/keae279.
Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register.
Rudi T, Zietemann V, Meissner Y, Zink A, Krause A, Lorenz H
RMD Open. 2024; 10(2).
PMID: 38580343
PMC: 11002391.
DOI: 10.1136/rmdopen-2023-003789.
Promising Therapeutic Effects of Embryonic Stem Cells-Origin Mesenchymal Stem Cells in Experimental Pulmonary Fibrosis Models: Immunomodulatory and Anti-Apoptotic Mechanisms.
Lee H, Jeong O, Park H, Lee S, Bok E, Kim M
Immune Netw. 2024; 23(6):e45.
PMID: 38188598
PMC: 10767550.
DOI: 10.4110/in.2023.23.e45.
Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.
Nakafero G, Grainge M, Williams H, Card T, Taal M, Aithal G
BMJ. 2023; 381:e074678.
PMID: 37253479
PMC: 10227711.
DOI: 10.1136/bmj-2022-074678.
Australian recommendations on perioperative use of disease-modifying anti-rheumatic drugs in people with inflammatory arthritis undergoing elective surgery.
Buchbinder R, Glennon V, Johnston R, Brennan S, Fong C, Edward May S
Intern Med J. 2023; 53(7):1248-1255.
PMID: 37067924
PMC: 10946831.
DOI: 10.1111/imj.16073.
Altered IL-6 signalling and risk of tuberculosis disease: a meta-analysis and Mendelian randomisation study.
Hamilton F, Schurz H, Yates T, Gilchrist J, Moller M, Naranbhai V
medRxiv. 2023; .
PMID: 36798349
PMC: 9934798.
DOI: 10.1101/2023.02.07.23285472.
Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series.
Malik M, Jones B, Williams E, Kurukulaaratchy R, Holroyd C, Mason A
Rheumatol Adv Pract. 2023; 7(1):rkad018.
PMID: 36789243
PMC: 9923700.
DOI: 10.1093/rap/rkad018.
Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study.
Venerito V, Manfredi A, Carletto A, Gentileschi S, Atzeni F, Guiducci S
J Clin Med. 2023; 12(3).
PMID: 36769604
PMC: 9917598.
DOI: 10.3390/jcm12030957.
Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study.
Lee S, Shin K, Jung J, Suh C, Kim J, Kim H
BioDrugs. 2023; 37(2):247-257.
PMID: 36757601
DOI: 10.1007/s40259-023-00578-6.
Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment.
Wu D, Luo Y, Li T, Zhao X, Lv T, Fang G
Front Immunol. 2023; 13:1051082.
PMID: 36618407
PMC: 9817137.
DOI: 10.3389/fimmu.2022.1051082.
[National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic...].
Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-Furst F
Z Rheumatol. 2022; 82(2):163-174.
PMID: 36342525
PMC: 9981509.
DOI: 10.1007/s00393-022-01274-6.
